These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18458136)

  • 81. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
    Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
    Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.
    Fleischhacker M; Radecke C; Schulz B; Ruhnke M
    Eur J Clin Microbiol Infect Dis; 2008 Feb; 27(2):127-31. PubMed ID: 18057972
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
    Nguyen MH; Yu CY
    J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
    [TBL] [Abstract][Full Text] [Related]  

  • 84. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.
    Fiori B; Posteraro B; Torelli R; Tumbarello M; Perlin DS; Fadda G; Sanguinetti M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3031-5. PubMed ID: 21422210
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Echinocandin Susceptibility Profile of Fluconazole Resistant Candida Species Isolated from Blood Stream Infections.
    Deorukhkar SC; Saini S
    Infect Disord Drug Targets; 2016; 16(1):63-8. PubMed ID: 26648186
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 87. In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates.
    Maida CM; Milici ME; Oliveri S
    J Chemother; 2007 Jun; 19(3):277-82. PubMed ID: 17594922
    [TBL] [Abstract][Full Text] [Related]  

  • 88. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D; Watelle M; Nolard N
    Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In vitro activity of caspofungin and voriconazole against uncommon Candida spp.
    Enache-Angoulvant A; Girard A; Poirot JL; Hennequin C
    Int J Antimicrob Agents; 2009 Jun; 33(6):595-6. PubMed ID: 19162450
    [No Abstract]   [Full Text] [Related]  

  • 90. In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
    Najafzadeh MJ; Badali H; Illnait-Zaragozi MT; De Hoog GS; Meis JF
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1636-8. PubMed ID: 20086140
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.
    Espinel-Ingroff A; Alvarez-Fernandez M; Cantón E; Carver PL; Chen SC; Eschenauer G; Getsinger DL; Gonzalez GM; Govender NP; Grancini A; Hanson KE; Kidd SE; Klinker K; Kubin CJ; Kus JV; Lockhart SR; Meletiadis J; Morris AJ; Pelaez T; Quindós G; Rodriguez-Iglesias M; Sánchez-Reus F; Shoham S; Wengenack NL; Borrell Solé N; Echeverria J; Esperalba J; Gómez-G de la Pedrosa E; García García I; Linares MJ; Marco F; Merino P; Pemán J; Pérez Del Molino L; Roselló Mayans E; Rubio Calvo C; Ruiz Pérez de Pipaon M; Yagüe G; Garcia-Effron G; Guinea J; Perlin DS; Sanguinetti M; Shields R; Turnidge J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6725-32. PubMed ID: 26282428
    [TBL] [Abstract][Full Text] [Related]  

  • 92. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
    Miyazaki M; Horii T; Hata K; Watanabe NA; Nakamoto K; Tanaka K; Shirotori S; Murai N; Inoue S; Matsukura M; Abe S; Yoshimatsu K; Asada M
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.
    Hazen KC; Baron EJ; Colombo AL; Girmenia C; Sanchez-Sousa A; del Palacio A; de Bedout C; Gibbs DL;
    J Clin Microbiol; 2003 Dec; 41(12):5623-32. PubMed ID: 14662952
    [TBL] [Abstract][Full Text] [Related]  

  • 94. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
    Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
    Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
    [TBL] [Abstract][Full Text] [Related]  

  • 95. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
    Cota J; Carden M; Graybill JR; Najvar LK; Burgess DS; Wiederhold NP
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3926-8. PubMed ID: 16940061
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
    Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
    Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
    [TBL] [Abstract][Full Text] [Related]  

  • 97. In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
    Cantón E; Pemán J; Valentín A; Espinel-Ingroff A; Gobernado M
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3108-11. PubMed ID: 19380590
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.
    Oz Y; Dag I; Kiraz N
    Mycopathologia; 2012 Jan; 173(1):27-34. PubMed ID: 21842180
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.
    Jones RN; Castanheira M; Pfaller MA
    Antimicrob Agents Chemother; 2010 Sep; 54(9):4041-3. PubMed ID: 20547802
    [No Abstract]   [Full Text] [Related]  

  • 100. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.
    Lackner M; de Hoog GS; Verweij PE; Najafzadeh MJ; Curfs-Breuker I; Klaassen CH; Meis JF
    Antimicrob Agents Chemother; 2012 May; 56(5):2635-42. PubMed ID: 22290955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.